By Caroline Humer / Reuters
September 20, 2016
Timothy Lunceford Stevens, who suffers from autoimmune diseases and allergies, holds an EpiPen as he speaks to reporters during a protest against the price of EpiPens, outside the office of hedge fund manager John Paulson, August 30, 2016 in New York City.
Timothy Lunceford Stevens, who suffers from autoimmune diseases and allergies, holds an EpiPen as he speaks to reporters during a protest against the price of EpiPens, outside the office of hedge fund manager John Paulson, August 30, 2016 in New York City.
Drew Angerer—Getty Images

U.S. government spending on Mylan’s Epipen in the Medicare program for seniors and the disabled rose 1,151% from 2007 through 2014, while the number of Epipen users grew 164%, the Kaiser Family Foundation said on Tuesday in an analysis.

The spending figure excludes after-market manufacturer rebates that Mylan paid to the private insurers who manage the Medicare Part D program for pharmacy drugs on behalf of the government, it said.

Read More: Here’s Mylan’s Latest Strategy to Make You Shut Up about High EpiPen Prices

In 2007, when Mylan purchased Epipen, the Medicare program spent $7 million on the product for 79,980 users, Kaiser said. In 2014, that spending rose to $87.9 million for 211,500 users, Kaiser said.

Kaiser Family Foundation is a health policy research organization.

EDIT POST